We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$127B
1-Year Est. Return
44.11%
This Fund
S&P 500
This Quarter
Est. Return
+8.41%
1 Year Est. Return
+44.11%
3 Year Est. Return
+121.64%
5 Year Est. Return
+154.22%
10 Year Est. Return
+724.54%
AUM
$110B
AUM Growth
+$8.55B
(+8.4%)
Cap. Flow
+$733M
Cap. Flow
% of AUM
0.67%
Top 10 Holdings %
Top 10 Hldgs %
32.31%
Holding
285
New
9
Increased
94
Reduced
125
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$381M |
| 2 |
AstraZeneca
AZN
|
+$242M |
| 3 |
Citigroup
C
|
+$201M |
| 4 |
Bath & Body Works
BBWI
|
+$145M |
| 5 |
Hewlett Packard
HPE
|
+$125M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$267M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$160M |
| 3 |
Amgen
AMGN
|
+$148M |
| 4 |
Johnson & Johnson
JNJ
|
+$146M |
| 5 |
Medtronic
MDT
|
+$131M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.65% |
| 2 | Healthcare | 23.76% |
| 3 | Industrials | 15.73% |
| 4 | Consumer Discretionary | 8.92% |
| 5 | Financials | 7.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Gildan
GIL
$9.18B
| $64.9M | 0.06% |
2,401,800
-30,000
| -1% | -$765K |
|
152
IMAX
IMAX
$2.41B
| $64.8M | 0.06% |
1,904,530
+111,817
| +6% | +$3.64M |
|
|
NUVA
153
DELISTED
NuVasive, Inc.
NUVA
| $63.7M | 0.06% |
853,000
-900
| -0.1% | -$65.3K |
|
|
CTRA
154
DELISTED
Coterra Energy
CTRA
| $58M | 0.05% |
2,427,400
+603,400
| +33% | +$13.7M |
|
|
COL
155
DELISTED
Rockwell Collins
COL
| $55.5M | 0.05% |
+571,700
| New | +$53.7M |
|
156
Zimmer Biomet
ZBH
$17.3B
| $54.2M | 0.05% |
457,114
-6,386
| -1% | -$724K |
|
157
AbbVie
ABBV
$454B
| $53.8M | 0.05% |
826,345
-75,500
| -8% | -$4.75M |
|
158
Charter Communications
CHTR
$15.6B
| $53.3M | 0.05% |
162,900
| – | – |
|
159
Edwards Lifesciences
EW
$48.3B
| $52.7M | 0.05% |
1,680,000
| – | – |
|
|
LGF.B
160
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $52.6M | 0.05% |
2,157,500
+215,000
| +11% | +$5.45M |
|
|
LGF.A
161
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
| $51.8M | 0.05% |
1,950,000
+7,500
| +0.4% | +$204K |
|
162
General Dynamics
GD
$103B
| $51.6M | 0.05% |
275,500
+37,500
| +16% | +$6.93M |
|
163
Johnson Controls International
JCI
$87.4B
| $50.9M | 0.05% |
1,208,700
+40,000
| +3% | +$1.69M |
|
|
SREV
164
DELISTED
ServiceSource International, Inc.
SREV
| $50.5M | 0.05% |
13,014,636
+116,400
| +0.9% | +$552K |
|
165
PepsiCo
PEP
$184B
| $50.3M | 0.05% |
450,000
| – | – |
|
166
Newell Brands
NWL
$2.14B
| $50.1M | 0.05% |
1,061,760
+120,000
| +13% | +$5.69M |
|
|
TPCO
167
DELISTED
Tribune Publishing Company Common Stock
TPCO
| $49.3M | 0.04% |
3,539,193
-2,800
| -0.1% | -$38.4K |
|
|
SAVE
168
DELISTED
Spirit Airlines, Inc.
SAVE
| $48.5M | 0.04% |
914,724
-2,100
| -0.2% | -$112K |
|
169
GSK
GSK
$102B
| $46.1M | 0.04% |
875,188
| – | – |
|
170
American Express
AXP
$233B
| $45.5M | 0.04% |
574,600
| – | – |
|
|
NVDQ
171
DELISTED
Novadaq Technologies Inc.
NVDQ
| $44.1M | 0.04% |
5,655,849
+12,400
| +0.2% | +$87.9K |
|
|
SIOX
172
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $43M | 0.04% |
359,866
+269,928
| +300% | +$28.3M |
|
173
NN Inc
NNBR
$264M
| $43M | 0.04% |
1,705,000
+136,500
| +9% | +$2.85M |
|
|
ASNA
174
DELISTED
Ascena Retail Group, Inc.
ASNA
| $42.1M | 0.04% |
494,205
| – | – |
|
175
Travelers Companies
TRV
$78.5B
| $41.8M | 0.04% |
347,100
| – | – |
|
Similar funds
Primecap Management's Q1 2017 Portfolio in Review
As of Q1 2017, Primecap Management held 285 positions worth $110B, up 8.4% from $102B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Trading was light in Q1 2017: portfolio turnover was 4.2%. Primecap Management opened 9 new positions and exited 3, leaving the 285-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Industrials.
- Primecap Management's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 7,741,094 shares worth $422M.
- Primecap Management added most to AstraZeneca in Q1 2017, an estimated $242M increase.
- Primecap Management's biggest Q1 2017 reduction was Intel, cutting an estimated $267M.
- Primecap Management fully exited C.H. Robinson in Q1 2017, selling an estimated $14.4M.
- Primecap Management's ten largest holdings make up 32% of its $110B portfolio in Q1 2017.
- Primecap Management opened 9 new positions and closed 3 in Q1 2017.
- Primecap Management's portfolio value rose 8.4% quarter-over-quarter to $110B.
Based on Primecap Management's 13F filing for Q1 2017, filed 12 May 2017.